ClinicalTrials.gg
Sign In

Carcinosarcoma clinical trials

The registry lists 60 studies for Carcinosarcoma across more than 10 countries. 12 are recruiting or about to start. 24 of them are mainly about Carcinosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.

Get an email when these change. Save the Carcinosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
19
Active, not recruiting
13
Recruiting
11
Terminated
8
Status unknown
4
Withdrawn
3

Phase

Phase 2
39
Phase 1
12
Phase 3
6

Where

United States
42
Canada
8
United Kingdom
6
Korea, Republic of
4
Italy
3
Germany
3

Who runs them

National Cancer Institute (NCI) (16) · Memorial Sloan Kettering Cancer Center (5) · Mayo Clinic (4) · Leap Therapeutics, Inc. (2) · Australia New Zealand Gynaecological Oncology Group (2) · NRG Oncology (1) · Ohio State University Comprehensive Cancer Center (1) · pharmaand GmbH (1)

What is being tested here

Drugs under test in Carcinosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Mirvetuximab soravtansine101
Neoantigen Peptide Vaccine101
Dordaviprone101
Nivolumab005
Paclitaxel004
Carboplatin014
Cediranib002
Pembrolizumab022
Ceralasertib002
Capivasertib001

Drug classes tested here Immune checkpoint inhibitors 10 · Tyrosine kinase inhibitors (TKIs) 6 · PARP inhibitors 3

Coming up

5phase 3 studies under way
8studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 11 Carcinosarcoma studies recruiting now, 11 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (27%) take children under 18. 5 (45%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
101 (9%)1 (9%)
1811 (100%)6 (55%)
3011 (100%)6 (55%)
4011 (100%)6 (55%)
5011 (100%)6 (55%)
6511 (100%)6 (55%)
7511 (100%)6 (55%)
8511 (100%)6 (55%)

Across all 60 studies, recruiting or not: 3% stop at 75 or younger and 0% at 65; 15% take children; 67% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinosarcoma studies take

Of 22 phase 2 interventional studies under Carcinosarcoma, half reached primary completion within 74 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 274 mo42–111 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 60. Browse all 60 → or search them.